Newsroom

18

February 2019

Monday

The Board of Directors of iX Biopharma Ltd. wishes to announce that the Company has entered into a sale and purchase agreement with Eurofins Australia New Zealand Holding Pty Ltd (the “Purchaser”), an independent third party, on 15 February 2019 in respect of the proposed disposal of the Company’s entire shareholding interest (comprising 20 ordinary shares) in the Company’s wholly-owned subsidiary, Chemical Analysis Pty Ltd to the Purchaser. 

More information on the proposed disposal of the laboratory testing business can be found here

11

February 2019

Monday

iX Biopharma Ltd. has reported results for the second financial quarter and first half-year ended 31 December 2018 (unaudited).

The second quarter financial statements for the period can be found here.

12

November 2018

Monday

iX Biopharma Ltd. has reported results for the first quarter ended 30 September 2018 (unaudited). 

The first quarter financial statements for the period can be found here.

05

November 2018

Monday

iX Biopharma Ltd will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark. Dr Janakan Krishnarajah, iX Biopharma’s Chief Medical Officer, will be presenting the results on 6 November 2018 at 3:00pm (GMT+1).  

More information can be found in the attached press release. The presentation slides can be accessed here.

27

September 2018

Thursday

iX Biopharma Ltd has published its Annual Report for FY2018.

The Annual Report can be found here, together with the Notice of AGM

05

September 2018

Wednesday

Specialty pharmaceutical company iX Biopharma Ltd is pleased to announce the success of its Phase 2 multi-dose clinical study (“KET010”) for Wafermine, its sublingual ketamine wafer for pain management.  The results confirm Wafermine’s efficacy, safety and good tolerability in patients experiencing moderate to severe acute, post-operative pain.

Following the successful results of KET010, iX Biopharma is currently preparing for its End-of-Phase-2 (EOP2) meeting with the US Food and Drug Administration to discuss the Phase 3 Wafermine clinical trial programme. 

Beyond post-operative pain, Wafermine also opens up new possibilities in the management of procedural pain, such as burns dressing changes, in the emergency department and for pre-hospital care.

More information can be found in the attached press release. The KET010 Top-line results summary can be viewed at this link.

27

August 2018

Monday

iX Biopharma Ltd. has reported results for the fourth financial quarter ended 30 June 2018 (unaudited).

FY18 saw the Group transition from a substantially R&D-based organisation to encompass production and revenue generation.

More information can be found in the attached press release. The fourth quarter financial statements for the period can be found here.

06

August 2018

Monday

iX Biopharma Ltd. is pleased to announce that it has received the approval by Therapeutic Goods Administration, the regulatory authority in Australia, for a sildenafil drug delivered using an oral capsule for the treatment of male erectile dysfunction. The product, which was formerly referred to as XCalibur, will be available under the brand name SILCAP in Australia. 

SILCAP is a generic version of Viagra® and will compete in the growing generic male erectile dysfunction market. Unlike existing sildenafil options in the market which are delivered in tablet form, SILCAP is delivered using a novel, small capsule and gives patients who dislike or are unable to swallow tablets an alternative dose form. SILCAP is the first capsule sildenafil product to obtain marketing approval in Australia. 

More information can be found in the attached press release.

19

June 2018

Tuesday

iX Biopharma Ltd. is pleased to announce the approval by Therapeutic Goods Administration, the regulatory authority in Australia, for WAFESIL (sublingual sildenafil wafer) formerly referred to as PheoniX, for the treatment of male erectile dysfunction.  

WAFESIL is a new dose form of sildenafil delivered using iX Biopharma’s proprietary drug delivery technology, WaferiX, which consists of a fast-dissolving wafer placed sublingually (under the tongue), allowing sildenafil to be administered safely, conveniently and rapidly into the blood stream. WAFESIL is the Group’s first pharmaceutical product utilising WaferiX to reach approval and registration. 

More information can be found in the attached press release

10

May 2018

Thursday

iX Biopharma Ltd. has reported results for the third financial quarter ended 31 March 2018 (unaudited).

Meanwhile, the Group expanded its Wafermine Phase 2 Study to include soft tissue post-surgical pain.

More information can be found in the attached press release. The third quarter financial statements for the period can be found here.

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com